NeoGenomics expects FY23 Adjusted EBITDA loss of $(27)M-$(22)M.
NeoGenomics Forecasts FY23 Revenues Of $545M-$555M Vs. $535.08M Estimate
NeoGenomics expects FY23 Adjusted EBITDA loss of $(27)M-$(22)M.
Related Posts
Yellen Warns Of Economic Chaos, Gates – The ‘Nuclear Energy Evangelist,’ Buffett Stands By To Support Banks And More: 5 Key Stories You May Have Missed From The Weekend
News out of Warren Buffett-led Berkshire Hathaway, Inc.’s (NYSE:BRK) (NYSE:BRK) annual shareholder meeting held in Omaha, Nebraska over…
Top 3 Tech And Telecom Stocks You May Want To Dump In June
As of June 4, 2024, three stocks in the communication services sector could be flashing a real warning…
CORRECTION: The Cigna Group Announced Late Friday It Has Settled Pending Legal Issues Related To Past Medicare Advantage Risk Adjustment Practices And Will Pay ~$172M Under Agreement With Federal Government
The Cigna Group (NYSE:CI) announced it has fully resolved pending legal matters related to certain past Medicare Advantage risk adjustment practices. Under agreements with the federal government, The Cigna Group will pay